摘要
Background ApoA1 as a key part of high density lipoprotein（HDL） has an important role in lipid metabo- lism. Diabetic patients often have disorders of lipid metabolism and apoA1 reduction. However, the benefits of fe- nofibrate in diabetes remain unclear as it increases the expression of apoA1. Methods A total of 80 patients with type 2 diabetes（40 mens, 40 femal） were collected in First Affiliated Hospital of Gannan Medical Universi- ty. According to the level of apoA1, subjects were assigned to apoA1 normal experimental group （A1 group, 20 cases） and apoA1 normal control group （A2 group, 20 cases）, apoA1 reduction experimental group （A3 group, 20 cases）, apoA1 reduction control group （A4 group 20 cases）. The control group was only given conventional hypo- glycemic therapy; Experimental group was given conventional hypoglycemic therapy and fenofibrate 200 mg/d treatment. The blood lipid and glucose were monitored after two-months treatment. Result After treatment with fenofibrate, the level of apoA1 in the experimental group was increased （A1 1.28 ± 0.05 vs. 1.39 ± 0.06; A3 0.81 ± 0.08 vs. 1.00 ± 0.11 ） and the lipid disorder was improved （A1 group TC 5.58 ± 0.32 vs. 5.19 ± 0.34, P= 0.01; TG 2.69 ± 0.07 vs. 2.52 ± 0.11, P= 0.013; HDL 1.30 ± 0.09 vs. 1.38 ± 0.05, P= 0.04; LDL 2.28 ± 0.15 vs. 2.19 ± 0.15, P〈 0.01; A3 group TC 5.88 ± 0.11 vs. 5.62 ± 0.16, P〈 0.01; TG 2.92 ± 0.18 vs. 2.67 ± 0.28, P〈 0.01; HDL 1.14 ± 0.19 vs. 1.22 ± 0.16, P〈 0.01; LDL 2.48 ± 0.13 vs. 2.39 ± 0.11, P= 0.037）. The blood glucose was not changed in all treatment groups. Conclusion Fenofibrate can increase the level of apoA1 and improve lipid me- tabolism in type 2 diabetic patients, without affecting blood glucose.
Background ApoA1 as a key part of high density lipoprotein（HDL） has an important role in lipid metabo- lism. Diabetic patients often have disorders of lipid metabolism and apoA1 reduction. However, the benefits of fe- nofibrate in diabetes remain unclear as it increases the expression of apoA1. Methods A total of 80 patients with type 2 diabetes（40 mens, 40 femal） were collected in First Affiliated Hospital of Gannan Medical Universi- ty. According to the level of apoA1, subjects were assigned to apoA1 normal experimental group （A1 group, 20 cases） and apoA1 normal control group （A2 group, 20 cases）, apoA1 reduction experimental group （A3 group, 20 cases）, apoA1 reduction control group （A4 group 20 cases）. The control group was only given conventional hypo- glycemic therapy; Experimental group was given conventional hypoglycemic therapy and fenofibrate 200 mg/d treatment. The blood lipid and glucose were monitored after two-months treatment. Result After treatment with fenofibrate, the level of apoA1 in the experimental group was increased （A1 1.28 ± 0.05 vs. 1.39 ± 0.06; A3 0.81 ± 0.08 vs. 1.00 ± 0.11 ） and the lipid disorder was improved （A1 group TC 5.58 ± 0.32 vs. 5.19 ± 0.34, P= 0.01; TG 2.69 ± 0.07 vs. 2.52 ± 0.11, P= 0.013; HDL 1.30 ± 0.09 vs. 1.38 ± 0.05, P= 0.04; LDL 2.28 ± 0.15 vs. 2.19 ± 0.15, P〈 0.01; A3 group TC 5.88 ± 0.11 vs. 5.62 ± 0.16, P〈 0.01; TG 2.92 ± 0.18 vs. 2.67 ± 0.28, P〈 0.01; HDL 1.14 ± 0.19 vs. 1.22 ± 0.16, P〈 0.01; LDL 2.48 ± 0.13 vs. 2.39 ± 0.11, P= 0.037）. The blood glucose was not changed in all treatment groups. Conclusion Fenofibrate can increase the level of apoA1 and improve lipid me- tabolism in type 2 diabetic patients, without affecting blood glucose.
基金
supported by the grant from the project of natural science fund of Jiangxi province(NO.20114BAB205007)
